Status:
COMPLETED
Glycine Treatment of Prodromal Symptoms
Lead Sponsor:
Yale University
Collaborating Sponsors:
Stanley Medical Research Institute
Conditions:
Schizophrenia
Eligibility:
All Genders
14-35 years
Phase:
PHASE2
Brief Summary
This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.
Eligibility Criteria
Inclusion
- age 14-35
- meets SIPS criteria for psychosis prodrome
Exclusion
- current antipsychotic medication
- more than 4 weeks of antipsychotic medication lifetime
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2004
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00268749
Start Date
July 1 2002
End Date
November 1 2004
Last Update
March 29 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.